Nektar Therapeutics to Participate in Upcoming Investor Conferences
Nektar Therapeutics (NKTR) has announced its participation in two major healthcare conferences. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes on November 13, 2024, at 1:15 p.m. ET, and at the Piper Sandler 36th Annual Healthcare Conference in New York on December 4, 2024, at 1:00 p.m. ET.
Both presentations will be available via webcasts on the company's investor relations website, with replays accessible for 30 days. Interested parties seeking one-on-one meetings with management should contact their respective bank representatives.
Nektar Therapeutics (NKTR) ha annunciato la sua partecipazione a due importanti conferenze sanitarie. L'azienda presenterà alla UBS Global Healthcare Conference a Rancho Palos Verdes il 13 novembre 2024, alle 13:15 ET, e alla Piper Sandler 36th Annual Healthcare Conference a New York il 4 dicembre 2024, alle 13:00 ET.
Entrambe le presentazioni saranno disponibili tramite webcast sul sito web delle relazioni con gli investitori dell'azienda, con riproduzioni accessibili per 30 giorni. Le parti interessate che desiderano incontri individuali con la direzione devono contattare i rispettivi rappresentanti bancari.
Nektar Therapeutics (NKTR) ha anunciado su participación en dos importantes conferencias de salud. La empresa presentará en la UBS Global Healthcare Conference en Rancho Palos Verdes el 13 de noviembre de 2024, a la 1:15 p.m. ET, y en la Piper Sandler 36th Annual Healthcare Conference en Nueva York el 4 de diciembre de 2024, a la 1:00 p.m. ET.
Ambas presentaciones estarán disponibles a través de webcasts en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante 30 días. Las partes interesadas que deseen reuniones individuales con la dirección deben contactar a sus respectivos representantes bancarios.
Nektar Therapeutics (NKTR)는 두 개의 주요 의료 회의에 참여할 것이라고 발표했습니다. 이 회사는 2024년 11월 13일 오후 1시 15분 ET에 랜초 팔로스 베르데스에서 열리는 UBS Global Healthcare Conference와 2024년 12월 4일 오후 1시 ET에 뉴욕에서 열리는 Piper Sandler 제36회 연례 의료 회의에서 발표할 예정입니다.
두 발표 모두 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 30일 동안 다시 시청할 수 있습니다. 경영진과의 일대일 미팅을 원하는 이해관계자는 각 은행 대표에게 연락해야 합니다.
Nektar Therapeutics (NKTR) a annoncé sa participation à deux grandes conférences sur la santé. L'entreprise fera une présentation lors de la UBS Global Healthcare Conference à Rancho Palos Verdes le 13 novembre 2024, à 13h15 ET, et à la Piper Sandler 36th Annual Healthcare Conference à New York le 4 décembre 2024, à 13h00 ET.
Les deux présentations seront disponibles via des webcasts sur le site des relations investisseurs de l'entreprise, avec des rediffusions accessibles pendant 30 jours. Les parties intéressées souhaitant des réunions individuelles avec la direction doivent contacter leurs représentants bancaires respectifs.
Nektar Therapeutics (NKTR) hat die Teilnahme an zwei wichtigen Gesundheitskonferenzen angekündigt. Das Unternehmen wird am 13. November 2024 um 13:15 Uhr ET auf der UBS Global Healthcare Conference in Rancho Palos Verdes und am 4. Dezember 2024 um 13:00 Uhr ET auf der Piper Sandler 36th Annual Healthcare Conference in New York präsentieren.
Beide Präsentationen werden über Webcasts auf der Website der Investorenbeziehungen des Unternehmens verfügbar sein, wobei Wiederholungen 30 Tage lang zugänglich sind. Interessierte Parteien, die Einzelgespräche mit dem Management wünschen, sollten ihre jeweiligen Bankvertreter kontaktieren.
- None.
- None.
- UBS Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, November 13, 2024 at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time – webcast link here
- Piper Sandler 36th Annual Healthcare Conference in
New York, NY on Wednesday, December 4, 2024 at 1:00 p.m. Eastern Time / 4:00 p.m. Pacific Time – webcast link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Vivian Wu
Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-upcoming-investor-conferences-302297943.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the UBS Global Healthcare Conference 2024?
When is NKTR presenting at the Piper Sandler Healthcare Conference 2024?
How long will the NKTR conference presentation replays be available?
How can investors arrange meetings with NKTR management at these conferences?
